Stargardt programs address ABCA4 payload constraints via dual-AAV platforms (VG801, AAVB-039) and explore first ...

The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host a free webinar for eye care professionals to explore the ...

Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that results from its clinical study of ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Back ...

Sunir Garg, MD, expresses excitement about attending AAO 2025 and focuses on several topics to be discussed. These include the benefits and potential vision risks of GLP-1 inhibitors in patients with ...

Cells along the outer edge of the retina begin to swell and multiply before memory problems appear. That subtle shift, ...

Opus Genetics targets inherited retinal diseases with one-dose AAV gene augmentations. Read why IRD stock is a Buy.

The Korea Research Institute of Standards and Science (KRISS) has developed a retina-mimicking eye phantom that faithfully replicates the structural layers and microvascular network of the human ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. A new study may transform ...

Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.

BioAge Labs (NASDAQ:BIOA) outlined its strategy and near-term clinical plans at Oppenheimer’s 36th Annual Life Science Conference, emphasizing its focus on using human aging biology to develop ...